Literature DB >> 19847813

Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model.

Stephanie J Gros1, Thorsten Dohrmann, Kersten Peldschus, Paulus G Schurr, Jussuf T Kaifi, Tatyana Kalinina, Uta Reichelt, Oliver Mann, Tim G Strate, Gerhard Adam, Robert M Hoffman, Jakob R Izbicki.   

Abstract

We describe the development of an aggressive orthotopic metastatic model of esophageal cancer, which is visualized in real time with combined magnetic resonance imaging (MRI) and fluorescence imaging. The aim of the study was to describe the development of a novel model of metastatic tumor disease of esophageal carcinoma and use this model to evaluate fluorescence and MRI in early detection of local and metastatic disease. The human esophageal adenocarcinoma cell line PT1590 was stably transfected with green fluorescent protein (GFP). Nude mice were orthotopically implanted with PT1590-GFP cells. Orthotopic tumor growth as well as metastatic spread was examined by fluorescence imaging and high-resolution MRI at defined intervals after orthotopic implantation. Highly aggressive novel fluorescent cell lines were isolated from metastatic tissues and put into culture. After implantation of these cells, 100% of the animals developed orthotopic primary tumors. In 83% of animals, metastatic spread to liver, lung and lymph nodes was observed. Primary tumor growth could be visualized with fluorescence imaging and with MRI with high correlation between the 2 methods. Fluorescence imaging allows fast, sensitive, and economical imaging of the primary and metastatic tumor without anesthesia. With MRI, anatomical structures are visualized more precisely and tumors can be more accurately localized to specific organs. This model should prove highly useful to understand esophageal carcinoma and to identify novel therapeutics for this treatment-resistant disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19847813     DOI: 10.1002/ijc.24980

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Authors:  Theresa D Ahrens; Sylvia Timme; Jens Hoeppner; Jenny Ostendorp; Sina Hembach; Marie Follo; Ulrich T Hopt; Martin Werner; Hauke Busch; Melanie Boerries; Silke Lassmann
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

2.  Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.

Authors:  Arup Bhattacharya; Steve G Turowski; Ivan Dominguez San Martin; Ashwani Rajput; Youcef M Rustum; Robert M Hoffman; Mukund Seshadri
Journal:  Anticancer Res       Date:  2011-02       Impact factor: 2.480

3.  Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases.

Authors:  Sergio Lavilla-Alonso; Gerd Bauerschmitz; Usama Abo-Ramadan; Juha Halavaara; Sophie Escutenaire; Iulia Diaconu; Turgut Tatlisumak; Anna Kanerva; Akseli Hemminki; Sari Pesonen
Journal:  J Transl Med       Date:  2010-08-23       Impact factor: 5.531

4.  MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway.

Authors:  Ya-Fei Zhang; An-Ran Zhang; Bi-Cheng Zhang; Zhi-Guo Rao; Jian-Fei Gao; Mu-Han Lv; Yu-Yun Wu; Su-Min Wang; Rong-Quan Wang; Dian-Chun Fang
Journal:  Mol Biol Rep       Date:  2012-10-30       Impact factor: 2.316

Review 5.  Imaging preclinical tumour models: improving translational power.

Authors:  Marion de Jong; Jeroen Essers; Wytske M van Weerden
Journal:  Nat Rev Cancer       Date:  2014-06-19       Impact factor: 60.716

6.  New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice.

Authors:  Shuai Song; Dong Chang; Yong Cui; Jian Hu; Min Gong; Kai Ma; Fang Ding; Zhi-Hua Liu; Tian-You Wang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

7.  Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

Authors:  Astrid Drenckhan; Tobias Grob; Anna Dupree; Thorsten Dohrmann; Oliver Mann; Jakob R Izbicki; Stephanie J Gros
Journal:  Langenbecks Arch Surg       Date:  2014-07-29       Impact factor: 3.445

8.  Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.

Authors:  Jon G Quatromoni; Jarrod D Predina; Pratik Bhojnagarwala; Ryan P Judy; Jack Jiang; Elizabeth M De Jesus; Veena Kapoor; Guanjun Cheng; Olugbenga T Okusanya; Evgeniy Eruslanov; Sunil Singhal
Journal:  J Immunother       Date:  2014-06       Impact factor: 4.456

9.  Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging.

Authors:  Henrike Caysa; Stefan Hoffmann; Jana Luetzkendorf; Lutz Peter Mueller; Susanne Unverzagt; Karsten Mäder; Thomas Mueller
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Authors:  Stephanie J Gros; Nina Kurschat; Astrid Drenckhan; Thorsten Dohrmann; Evelyn Forberich; Katharina Effenberger; Uta Reichelt; Robert M Hoffman; Klaus Pantel; Jussuf T Kaifi; Jakob R Izbicki
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.